Polartechnics Limited

The Australian shares ended with little changes on Friday. The S&P/ASX200 index just added 1 point to 3776.7 points, while the broader All Ordinaries gained 2.5 points to 3728.1. The local market is likely to be lifted on the back of the stronger metals prices. Today Rio Tinto's Australian annual meeting will also be the market focus.

Polartechnics (ASX:PLT)(PINK:PLTFF) proprietary self-sampling device, CerviScreen, has now been adapted to test for STI's including Chlamydia, Gonorrhoea and Trichomoniasis for both men and women. The new self-sampling target market for the STI device is sexually active men and women aged 15 to 50.

Polartechnics Limited (ASX:PLT)(PINK:PLTFF) today announced it had reached a strategic agreement with its preferred business partners, Genera Biosystems and Healthscope, for the commercialisation of CerviScreen, which is a new device to identify sexually transmitted Human Papillomavirus (HPV) using self-sampled specimens.